Cargando…
Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438258/ https://www.ncbi.nlm.nih.gov/pubmed/23383730 http://dx.doi.org/10.18553/jmcp.2013.19.s1.1 |
| _version_ | 1785092750593490944 |
|---|---|
| author | Barnes, Christopher J. Caon, Christina Foley, John F. Friedman, Mark Menzin, Joseph Nair, Kavita V. Nichols, Christine Olvey, Eleanor L. Owens, Gary M. Pill, Michael W. Skrepnek, Grant H. White, Leigh Ann Zerkowski, Kristine |
| author_facet | Barnes, Christopher J. Caon, Christina Foley, John F. Friedman, Mark Menzin, Joseph Nair, Kavita V. Nichols, Christine Olvey, Eleanor L. Owens, Gary M. Pill, Michael W. Skrepnek, Grant H. White, Leigh Ann Zerkowski, Kristine |
| author_sort | Barnes, Christopher J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10438258 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Academy of Managed Care Pharmacy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104382582023-08-21 Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care Barnes, Christopher J. Caon, Christina Foley, John F. Friedman, Mark Menzin, Joseph Nair, Kavita V. Nichols, Christine Olvey, Eleanor L. Owens, Gary M. Pill, Michael W. Skrepnek, Grant H. White, Leigh Ann Zerkowski, Kristine J Manag Care Pharm Supplement Academy of Managed Care Pharmacy 2013-01 /pmc/articles/PMC10438258/ /pubmed/23383730 http://dx.doi.org/10.18553/jmcp.2013.19.s1.1 Text en Copyright © 2013, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Supplement Barnes, Christopher J. Caon, Christina Foley, John F. Friedman, Mark Menzin, Joseph Nair, Kavita V. Nichols, Christine Olvey, Eleanor L. Owens, Gary M. Pill, Michael W. Skrepnek, Grant H. White, Leigh Ann Zerkowski, Kristine Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care |
| title | Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care |
| title_full | Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care |
| title_fullStr | Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care |
| title_full_unstemmed | Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care |
| title_short | Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care |
| title_sort | intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for ms: considerations for managed care |
| topic | Supplement |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438258/ https://www.ncbi.nlm.nih.gov/pubmed/23383730 http://dx.doi.org/10.18553/jmcp.2013.19.s1.1 |
| work_keys_str_mv | AT barneschristopherj intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT caonchristina intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT foleyjohnf intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT friedmanmark intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT menzinjoseph intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT nairkavitav intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT nicholschristine intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT olveyeleanorl intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT owensgarym intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT pillmichaelw intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT skrepnekgranth intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT whiteleighann intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare AT zerkowskikristine intramuscularinterferonbeta1aandevolvingtreatmentoptionsandoutcomesmeasurementformsconsiderationsformanagedcare |